No connection

Search Results

DNA

BEARISH
$7.87 Live
Ginkgo Bioworks Holdings, Inc. · NYSE
Target $8.67 (+10.1%)
$5.37 52W Range $17.58
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 26, 2026
Market cap
$487.34M
P/E
N/A
ROE
-51.1%
Profit margin
-183.8%
Debt/Equity
0.86
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and operational deterioration. Despite a strong current ratio of 4.92 providing a short-term liquidity buffer, the company is facing a systemic collapse in growth with YoY revenue declining by 23.80%. Massive negative operating margins (-209.74%) and a catastrophic 5-year price decline of 98.1% suggest a failing business model. The combination of shrinking top-line revenue and bearish insider selling confirms a high-risk profile.

Key Strengths

High liquidity with a Current Ratio of 4.92
Strong Gross Margin of 72.39% indicating core product value
Trading slightly below book value (P/B 0.90)
Recent EPS surprises have been positive (beating low expectations)
High Quick Ratio (4.66) suggests minimal reliance on inventory for liquidity

Key Risks

Severe financial instability (Piotroski F-Score 1/9)
Negative revenue growth (-23.80% YoY) indicating loss of market traction
Extreme cash burn with an operating margin of -209.74%
Strong bearish insider sentiment with 10 sell transactions and 0 buys
Long-term value destruction with a -98.1% 5-year return
AI Fair Value Estimate
Based on comprehensive analysis
$6.5
-17.4% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
11
Weak
Value
30
Future
10
Past
5
Health
10
Dividend
0
AI Verdict
High Risk / Value Trap
Key drivers: Piotroski F-Score 1/9, Negative Revenue Growth, Extreme Operating Losses, Bearish Insider Activity
Confidence
90%
Value
30/100

Ref P/E N/A, P/B 0.90

Positives
  • P/B ratio of 0.90 suggests the stock is priced near its accounting value
Watchpoints
  • No P/E or PEG due to lack of earnings
  • Graham Number is non-calculable due to negative earnings
Future
10/100

Ref Revenue Growth -23.80%

Positives
  • Improving EPS trend (less negative)
Watchpoints
  • Revenue growth is negative (-23.8%)
  • Forward P/E remains negative
Past
5/100

Ref 5Y Change -98.1%

Positives
No standout positives identified.
Watchpoints
  • 5-year price change of -98.1%
  • Consistent history of missing earnings estimates in early years
Health
10/100

Ref Piotroski F-Score 1/9

Positives
  • Strong current and quick ratios
Watchpoints
  • Piotroski F-Score of 1/9 is a major red flag for insolvency/weakness
  • ROE of -51.08%
Dividend
0/100

Ref Dividend Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends given current losses

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$7.87
Analyst Target
$8.67
Upside/Downside
+10.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for DNA and closest competitors.

Updated 2026-04-24
DNA
Ginkgo Bioworks Holdings, Inc.
Primary
5Y
-98.1%
3Y
-83.7%
1Y
0.0%
6M
-42.0%
1M
+6.9%
1W
-2.0%
RGN
REGENXBIO Inc.
Peer
5Y
-72.0%
3Y
-49.8%
1Y
+59.8%
6M
-19.1%
1M
+14.6%
1W
+7.8%
AQS
Aquestive Therapeutics, Inc.
Peer
5Y
-27.7%
3Y
+432.4%
1Y
+47.8%
6M
-20.4%
1M
+5.2%
1W
-4.7%
BWA
BrainsWay Ltd.
Peer
5Y
+163.4%
3Y
+1289.2%
1Y
+184.8%
6M
+61.0%
1M
-3.2%
1W
-7.8%
KMD
Kamada Ltd.
Peer
5Y
+49.5%
3Y
+95.6%
1Y
+48.0%
6M
+28.6%
1M
+2.3%
1W
+0.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-2.17
PEG Ratio
N/A
P/B Ratio
0.9
P/S Ratio
2.86
EV/Revenue
2.79
EV/EBITDA
-1.77
Market Cap
$487.34M

Profitability

Profit margins and return metrics

Profit Margin -183.81%
Operating Margin -209.74%
Gross Margin 72.39%
ROE -51.08%
ROA -15.42%

Growth

Revenue and earnings growth rates

Revenue Growth -23.8%
Earnings Growth N/A
Q/Q Revenue Growth -23.84%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.86
Moderate
Current Ratio
4.92
Strong
Quick Ratio
4.66
Excellent
Cash/Share
$7.26

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
78.1%
Op. Margin
-209.7%
Net Margin
-241.8%
Total Assets
$1.1B
Liabilities
$0.6B
Equity
$0.5B
Debt/Equity
1.20x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05
$N/A
2026-02-26
$-0.77
+30.5% surprise
2025-11-06
$-1.45
-16.9% surprise
2025-08-07
$-1.1
+29.8% surprise

Healthcare Sector Comparison

Comparing DNA against 548 companies in the Healthcare sector (30 bullish, 163 neutral, 355 bearish)
Return on Equity (ROE)
-51.08%
This Stock
vs
-89.9%
Sector Avg
-43.2% (Below Avg)
Profit Margin
-183.81%
This Stock
vs
-16.4%
Sector Avg
+1020.8% (Superior)
Debt to Equity
0.86
This Stock
vs
2.71
Sector Avg
-68.1% (Less Debt)
Revenue Growth
-23.8%
This Stock
vs
126.74%
Sector Avg
-118.8% (Slower)
Current Ratio
4.92
This Stock
vs
4.53
Sector Avg
+8.5% (Better)

Similar Companies

Peer comparison within the same industry

DNA Ginkgo Bioworks...
BEARISH
Mkt Cap
$487M
P/E
-
ROE
-51.1%
Price
$7.87
RGNX REGENXBIO Inc.
BEARISH
Mkt Cap
$490M
P/E
-
ROE
-107.0%
Price
$9.49
 Compare with DNA
AQST Aquestive...
BEARISH
Mkt Cap
$490M
P/E
-
ROE
-%
Price
$4.02
 Compare with DNA
BWAY BrainsWay Ltd.
NEUTRAL
Mkt Cap
$491M
P/E
68.1
ROE
11.3%
Price
$12.26
 Compare with DNA
KMDA Kamada Ltd.
NEUTRAL
Mkt Cap
$491M
P/E
24.3
ROE
7.6%
Price
$8.49
 Compare with DNA

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

COEN STEVEN P.
Chief Financial Officer
Sell
2026-04-17
324 shares · $2,576
COEN STEVEN P.
Chief Financial Officer
Stock Award
2026-04-16
743 shares
COEN STEVEN P.
Chief Financial Officer
Sell
2026-04-13
33,171 shares · $212,759
CANTON BARTHOLOMEW
Beneficial Owner of more than 10% of a Class of Security
Sell
2026-04-10
124,727 shares · $802,494
COEN STEVEN P.
Chief Financial Officer
Stock Award
2026-04-10
73,921 shares
SHETTY RESHMA PADMINI
President
Sell
2026-04-10
124,727 shares · $802,494
CANTON BARTHOLOMEW
Beneficial Owner of more than 10% of a Class of Security
Sell
2026-04-09
26,271 shares · $175,067
CANTON BARTHOLOMEW
Beneficial Owner of more than 10% of a Class of Security
Stock Award
2026-04-09
251,786 shares
KELLY JASON R
Chief Executive Officer
Sell
2026-04-09
206,782 shares · $1,374,493
SHETTY RESHMA PADMINI
President
Sell
2026-04-09
26,271 shares · $175,067
SHETTY RESHMA PADMINI
President
Stock Award
2026-04-09
251,786 shares
CANTON BARTHOLOMEW
Beneficial Owner of more than 10% of a Class of Security
Stock Award
2026-04-08
55,476 shares
KELLY JASON R
Chief Executive Officer
Stock Award
2026-04-08
425,898 shares
SHETTY RESHMA PADMINI
President
Stock Award
2026-04-08
55,476 shares
COEN STEVEN P.
Chief Financial Officer
Sell
2026-03-16
708 shares · $4,768
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-07

Ginkgo Bioworks Holdings, Inc. filed a Current Report on April 7, 2026, likely to announce its first-quarter financial results or other material corporate developments.

8-K
8-K
2026-02-27

Ginkgo Bioworks Holdings, Inc. (DNA) filed an 8-K likely reporting its fourth quarter and full-year financial results.

8-K
8-K
2026-02-26

Ginkgo Bioworks Holdings, Inc. (DNA) likely filed this 8-K to announce its annual financial results or report a material corporate event.

10-K
10-K
2026-02-26

DNA filed its annual 10-K on February 26, 2026, providing comprehensive disclosures on its business operations and financial condition. The filing includes detailed sections on management's discussion and analysis of results of operations and a dedicated overview of the company's risk factors.

8-K
8-K
2025-12-23
10-Q
10-Q
2025-11-06

DNA filed its quarterly 10-Q report on November 6, 2025. The filing includes a dedicated section on risk factors under Item 1A, although specific financial highlights were not provided in the available excerpt.

8-K
8-K
2025-11-06

Ginkgo Bioworks Holdings, Inc. (DNA) filed a Form 8-K on November 6, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-09-04
8-K
8-K
2025-08-29

Ginkgo Bioworks Holdings, Inc. filed a current report on August 29, 2025, likely to announce its second-quarter financial results.

10-Q
10-Q
2025-08-07

DNA filed its quarterly 10-Q report on August 7, 2025. The filing includes a dedicated section on risk factors under Item 1A, although specific financial highlights and risk details were not provided in the available excerpt.

8-K
8-K
2025-08-07
8-K
8-K
2025-06-13
8-K
8-K
2025-05-21
10-Q
10-Q
2025-05-06
8-K
8-K
2025-05-06
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
HOLD
3 analysts
BTIG
2026-03-12
Maintains
Sell Sell
TD Cowen
2026-01-08
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning DNA from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile